Company to highlight results and development programs spanning muscle, brain, cardiovascular, kidney, bladder, eye, hair, skin, sexual health, pulmonary, hearing, orthopedic and regenerative medicine applications—with a central focus on endogenous Klotho stimulation and healthy longevity
HUNTINGTON BEACH, Calif. — September 14, 2026 — Lionheart Health, Inc., a regenerative health, bioelectric medicine and longevity technology company, today announced that it will present preclinical and clinical research from its expanding portfolio of bioelectric and regenerative technologies at the 2nd Annual Klotho Conference, September 18–19, 2026, in Miami, Florida.
The Klotho Conference brings together scientists, physicians, biotechnology innovators and longevity leaders to examine Klotho biology and emerging approaches for translating Klotho science into human applications.
Lionheart Health Founder, Executive Chairman and Co-CEO Howard J. Leonhardt is scheduled to present “Devices for Endogenous Klotho Stimulation and Results,” highlighting the company’s work developing programmable bioelectric signaling technologies designed to stimulate or modulate Klotho and complementary regenerative pathways.
Lionheart Health Chief Medical Officer Dr. Leslie Miller is also scheduled to present results from the company’s Klotho-Up™ healthspan program, including its integrated approach to muscle, brain, immune and whole-body healthy aging.
“Our objective is to move Klotho science from observation toward practical, measurable regenerative applications,” said Howard J. Leonhardt, Founder, Executive Chairman and Co-CEO of Lionheart Health. “We have built a platform designed to activate the body’s own regenerative signaling—including Klotho and complementary proteins—and are evaluating these technologies across multiple organ systems. At the Klotho Conference, we look forward to sharing both the data we have generated and the next generation of studies now moving forward.”
Broad Bioelectric and Regenerative Medicine Research Portfolio
Lionheart Health expects its conference presentation to summarize preclinical, clinical and translational work across a broad portfolio of programs. Development status and evidence levels vary by program, and a number of the technologies remain investigational for their proposed medical applications.
BodStim™ — Muscle, Mobility and Healthspan: Clinical research with Lionheart’s electrical muscle stimulation platform has reported improvements across measures of strength, mobility, muscle mass and functional performance. The research program also evaluates Klotho and other healthy-aging biomarkers, with selected studies reporting increases in circulating Klotho.
Brain Band™ / MemoryStim™ / DepressiStim™ — Brain Health: Early clinical research with Lionheart’s Brain Band platform has reported approximately 12%–34% improvements in memory measures, 15%–30% in attention/cognitive measures, 18%–35% in mood-related measures and 15%–45% reductions in stress-related measures in selected datasets. The program investigates bioelectric modulation of Klotho, BDNF, GDF10 and other regenerative signaling pathways.
PressureStim™ — Blood Pressure and Vascular Health: Investigational bioelectric programming is being evaluated for its potential to support vascular function and healthier blood-pressure regulation through neurovascular and regenerative signaling pathways.
Stem Cell Bra™ — Breast Tissue Regeneration: Lionheart’s investigational non-invasive breast-regeneration platform is designed to combine targeted bioelectric signaling with regenerative approaches intended to stimulate tissue repair, circulation, extracellular-matrix remodeling and stem-cell homing.
KlothoCell™ — Heart Regeneration: Building upon the Leonhardt’s core team earlier clinical experience with regenerative cell therapy for damaged myocardium, the MyoCell and MyoCell SDF-1 program formed a foundation part, and learning base, for Lionheart’s broader strategy for cardiovascular regeneration and heart-failure research. Lionheart Health has built on this original program to create new entirely new technology based on a klotho expressing cells in nutrient hydrogel platform with daily delivery supported by bioelectric stimulation controlled protein expressions.
KidneyCell™ — Kidney Regeneration: KidneyCell research investigates bioelectric and regenerative approaches intended to support renal tissue repair and kidney function, with particular interest in the relationship between kidney health, Klotho biology and systemic aging.
BladderCell™ — Bladder Health: Investigational programming is being developed to evaluate bioelectric signaling and regenerative pathways for bladder function, tissue health and neuromuscular control.
EyeCell™ — Vision and Retinal Health: Early clinical research involving the EyeCell program has reported improvement in 68.7% of treated eyes, stability in 18.8%, and a combined 87.5% non-decline rate in an early dataset of 16 eyes, with selected subjects achieving gains of up to four lines in best-corrected visual acuity.
VascuStim™ / Tisugen™ — Vascular Regeneration: Lionheart’s vascular programs combine bioelectric signaling with regenerative technologies under investigation for improving circulation, stimulating vascular repair and supporting angiogenic and tissue-regeneration pathways.
HairCell™ — Hair Regeneration: Early HairCell clinical experience has reported approximately 16.7% improvement in hair density at four weeks and approximately 30% at 12 weeks in selected subjects. The expanding HairCell Plus™ platform combines programmable bioelectric signaling with complementary regenerative modalities.
SkinStim™ — Skin Regeneration: SkinStim investigates bioelectric signaling of regenerative proteins and complementary modalities intended to improve skin quality, collagen-related pathways, circulation and tissue rejuvenation. Lionheart is developing SkinStim Plus™ as an integrated regenerative-aesthetics platform.
ErectiStim™ — Male Sexual Health: Investigational bioelectric programming is being studied for its potential to support circulation, vascular health, tissue regeneration and functional improvement associated with male sexual health.
TestiStim™ — Testicular and Hormonal Health: Lionheart is evaluating targeted bioelectric approaches intended to support testicular tissue health and regenerative signaling pathways associated with healthy endocrine and reproductive function.
ImplantStim™ — Implantable Regenerative Bioelectric Stimulation: Lionheart’s implantable micro-stimulation research represents a next-generation approach designed to provide localized, programmable stimulation of regenerative pathways, including potential Klotho expression and stem-cell homing.
BreatheStim™ — Lung and Respiratory Health: BreatheStim is being developed as a non-invasive bioelectric research platform directed toward respiratory function, pulmonary tissue health and regenerative signaling.
EarCell™ — Hearing Regeneration: EarCell research is investigating targeted stimulation of pathways associated with cochlear repair, neurotrophic signaling, hair-cell regeneration and synaptic health, including BDNF, Klotho and other regenerative signals.
Second Brain™ — Gut-Brain and Immune Health: Lionheart’s Second Brain program investigates bioelectric and multimodality approaches directed toward the gut-brain axis, microbiome, inflammation, immune function and systemic healthy-aging pathways.
OrthoStim Plus™ — Joint and Musculoskeletal Regeneration: Early OrthoStim clinical research has reported approximately 40%–65% reductions in pain, 35%–50% improvements in WOMAC measures and 12%–22% improvements in six-minute walk performance in selected subjects. OrthoStim Plus™ expands the platform by combining bioelectric signaling with complementary regenerative modalities.
A Common Biological Strategy: Stimulating the Body’s Own Regenerative Signals
Rather than developing a single Klotho intervention for a single organ, Lionheart Health is pursuing a broader platform strategy centered on controlled bioelectric modulation of endogenous regenerative biology.
The company’s research evaluates Klotho alongside complementary signaling targets involved in tissue repair, neuroplasticity, vascularization, muscle maintenance, inflammation control and stem-cell recruitment.
The long-term objective is to determine whether combinations of programmable bioelectric signaling, exercise stimulation, regenerative biologics and other complementary technologies can produce measurable improvements across multiple hallmarks and functional consequences of aging.
“Our hypothesis is that healthy longevity will ultimately require treating the body as an interconnected system rather than addressing aging organ by organ,” Leonhardt said. “Klotho may be one of the most important coordinating signals within that system. Our work is focused on developing practical technologies capable of repeatedly stimulating regenerative biology and then measuring the results.”
Two Lionheart Presentations September 19
The published Klotho Conference agenda includes two consecutive Lionheart-related presentations on Saturday, September 19:
11:30 a.m.–12:00 p.m. EDT — Howard Leonhardt:
Devices for Endogenous Klotho Stimulation and Results
12:05–12:35 p.m. EDT — Dr. Leslie Miller:
Klotho-Up Study Results for Heart, Kidney and Cardioascular Health Presented for XPRIZE Healthspan
Lionheart Octopus™ and BioLeonhardt Whole Body Regeneration Chamber
Lionheart Health will also present two of its most ambitious next-generation regenerative medicine platforms under development: the Lionheart Octopus™ Multiple Organ Regeneration System and the BioLeonhardt Whole Body Regeneration Chamber, described by the development team as a “womb for adults.” The Lionheart Octopus™ is being designed as a multi-organ regenerative platform capable of coordinating targeted delivery and bioelectric stimulation across multiple tissues and organ systems, with the long-term goal of activating Klotho expression, stem-cell homing, vascularization, tissue repair and other regenerative pathways in a controlled and programmable manner. The platform is intended to integrate Lionheart’s experience in bioelectric signaling with emerging cell, biologic and localized regenerative-delivery technologies.
The BioLeonhardt Whole Body Regeneration Chamber is an earlier-stage research and engineering concept intended to bring multiple regenerative modalities into a single controlled environment. The “womb for adults” concept is being designed to investigate combinations of programmable bioelectric stimulation, Klotho-focused regenerative signaling, red and near-infrared photobiomodulation, pulsed electromagnetic fields, neuromuscular stimulation, oxygenation and other complementary regenerative technologies. The long-term vision is to create a highly monitored environment capable of simultaneously supporting brain, cardiovascular, muscle, vascular, kidney, immune, skin and other tissue-rejuvenation programs rather than addressing aging one organ at a time.
Engineering development of these next-generation concepts has received support through the University of California, Irvine Capstone Engineering Program, which has provided engineering resources for Lionheart-affiliated regenerative technology development. Both systems remain under development and are intended as research platforms; specific therapeutic applications will require appropriate preclinical, clinical and regulatory evaluation.
“The Lionheart Octopus and Whole Body Regeneration Chamber represent where we believe regenerative medicine can ultimately go—away from isolated interventions and toward coordinated, measurable, multi-organ regeneration,” said Leonhardt. “Our long-term objective is to create an environment that gives the adult body many of the regenerative signals associated with development and youthful tissue repair, while precisely measuring the biological response.”
About Lionheart Health, Inc.
Lionheart Health, Inc. is a regenerative health, bioelectric medicine and longevity technology company developing non-invasive and implantable technologies designed to harness the body’s endogenous repair and regeneration mechanisms. Its research portfolio spans muscle, brain, cardiovascular, kidney, vascular, orthopedic, vision, hearing, pulmonary, aesthetic and whole-body healthspan applications.
The company’s development strategy combines programmable bioelectric signaling with complementary regenerative technologies and biomarker-driven health optimization, with particular emphasis on Klotho and other proteins associated with tissue repair and healthy aging.
Important Research and Regulatory Notice
Certain technologies, indications and biological mechanisms described in this release are investigational and have not been cleared or approved by the U.S. Food and Drug Administration for the diagnosis, treatment, cure or prevention of disease. Results cited from early-stage, pilot, observational or preclinical research should not be interpreted as establishing safety or efficacy for an unapproved medical indication. Larger controlled clinical studies may be required to confirm preliminary findings.
Conference Information
2nd Annual Klotho Conference
September 18–19, 2026
Miami, Florida
KlothoConference.com
Media / Corporate Contact
Lionheart Health, Inc.
Huntington Beach, California
http://www.LionheartLongevity.
Email: howard@LionheartLongevity.com